Fulgent Genetics (MEX:FLGT) Capex-to-Revenue : 0.06 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Fulgent Genetics's Capital Expenditure for the three months ended in Mar. 2024 was MXN-67.31 Mil. Its Revenue for the three months ended in Mar. 2024 was MXN1,070.21 Mil.

Hence, Fulgent Genetics's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.06.

Fulgent Genetics Capex-to-Revenue Historical Data

The historical data trend for Fulgent Genetics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Capex-to-Revenue Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

0.04

0.08

0.02

0.05

0.08

Fulgent Genetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial															0.03	0.18	0.06	0.04	0.06

Competitive Comparison of Fulgent Genetics's Capex-to-Revenue

For the Diagnostics & Research subindustry, Fulgent Genetics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Capex-to-Revenue falls into.

Fulgent Genetics Capex-to-Revenue Calculation

Fulgent Genetics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-376.947)	/	4909.173
	=	0.08

Fulgent Genetics's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-67.314)	/	1070.21
	=	0.06

Fulgent Genetics (MEX:FLGT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Fulgent Genetics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (MEX:FLGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.